July 17th 2020
May 20th 2020
Peter Voorhees, MD, discusses the benefit of monoclonal antibodies in multiple myeloma.
May 19th 2020
May 2nd 2020
Peter Voorhees, MD, discusses the evolution of idecabtagene vicleucel (ide-cel; bb2121) in the phase 2 KarMMa study in relapsed/refractory multiple myeloma.
February 5th 2020
Peter Voorhees, MD, discusses the role of CAR T-cell therapy in multiple myeloma.
January 23rd 2020
Peter Voorhees, MD, discusses the updated depth of response data that were reported in the GRIFFIN trial of patients with multiple myeloma.
September 12th 2019
Peter Voorhees, MD, physician, Levine Cancer Institute, Atrium Health, discusses the randomized phase II ELOQUENT-3 trial in relapsed/refractory multiple myeloma.
January 12th 2019
Peter Voorhees, MD, professor of medicine, UNC Lineberger Comprehensive Cancer Center, discusses the safety run-in of the Griffin study looking at daratumumab in myeloma.
April 28th 2018
Peter Voorhees, MD, physician, Levine Cancer Institute, discusses treatments for patients with relapsed multiple myeloma.
September 6th 2017
Peter Voorhees, MD, hematology, medical oncology, Carolinas HealthCare System, discusses optimal management of treatment-related adverse events (TRAEs) for patients with multiple myeloma.